Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Scios timeline

Scios timeline

DateEventOct 1994SCIO begins Phase II trials of Natrecor B-type natriuretic peptide in acute congestive heart failureJan 1995Enters into $100 million deal with Genentech to commercialize Auriculin atrial natriuretic peptideMay 1995Reports disappointing Phase III results of Auriculin to treat acute renal failure, although the peptide did reduce the need for dialysis in a prospectively defined subgroup of patients with oliguric ARF (abnormally low urine output)Oct 1995Begins Phase III trial of Auriculin in oliguric ARFApr 1996Grants Novo Nordisk rights to insulinotropin, which is in Phase II trials in

Read the full 888 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers